{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Grade 3 Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 4 or Higher Adverse Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"The maximum grade for each adverse event considered to be at least possibly related to treatment will be recorded. Frequency tables will be constructed.","groups":[{"description":"Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"paramType":"NUMBER","populationDescription":"Eighteen of the 19 participants accrued to the study were evaluable for adverse events.","reportingStatus":"POSTED","timeFrame":"Every 4 weeks during treatment (maximum duration was 44 weeks)","title":"Adverse Events Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0","type":"SECONDARY","unitOfMeasure":"participants"}